Altria and Reynolds American announce launch of new smokeless tobacco products without FDA approval; anti-smoking advocates express concerns over potential impact on youth health

Sep.01.2025

Altria and Reynolds American are rolling out smoke-free products without FDA approval due to delays. They highlight that illegal e-cigarettes, with candy flavors, are gaining market share while legal products await approval. Altria will release a new nicotine pouch in select states, and Reynolds will launch a disposable e-cigarette. Advocates fear these unauthorized products may attract new users and harm youth.

Key Points:

·The American tobacco companies Altria and Reynolds American have launched new smokeless products without receiving FDA marketing authorization.

·Anti-smoking advocates are concerned that these unauthorized products could attract new customers and potentially harm the health of adolescents.

According to a report from richmond on August 31, 2025, American tobacco companies Altria and Reynolds American are dissatisfied with the delayed approval of new tobacco products by the US FDA. They plan to launch smokeless alternatives without waiting for official FDA marketing authorization.

Altria and Reynolds both stated that the FDA gained jurisdiction over tobacco and nicotine products in 2009 under federal law, but has not made approval decisions within the legally prescribed time frame. At the same time, these companies pointed out that illegal e-cigarettes, due to their unknown ingredients and candy flavors appealing to young people, are quickly gaining market share, while many companies' legal products have been awaiting approval for a long time.

The FDA stated that all new tobacco products must receive approval before being sold in the US market, but as of August 31, only 39 e-cigarette products and 20 nicotine pouch products have been approved. However, Altria's subsidiary Helix plans to launch a new version of "on!" nicotine pouch in North Carolina, Texas, and Florida starting in the fall of 2025.

A spokesperson for Altria revealed that the company submitted a pre-market tobacco product application to the FDA in June 2024, and has met all regulatory requirements. They stated that the FDA's approval process is significantly exceeding the statutory 180-day timeline, which is severely impacting the company's market progress for their products.

At the same time, Reynolds plans to launch a new disposable e-cigarette called "Vuse One" in the fourth quarter of 2025 in South Carolina, Florida, and Georgia to advance the process of reducing tobacco harm.

Concerns have been raised by anti-smoking advocates regarding these actions. Smokeless tobacco products are often accused of attracting new customers, and the FDA's efforts to prevent youth smoking seem insufficient. Dave Lemmon of the Campaign for Tobacco-Free Kids pointed out that moves by companies like Altria and Reynolds appear to be bold introductions of unauthorized products to the market.

References:

[1] Altria, Reynolds moving new products to market without FDA OK

Also Read:

[1] Iowa E-Cigarette Law Challenged: Industry Claims New Rules Will Destroy the Industry and Violate FDA Enforcement Discretion

[2] Arkansas to Ban Non-FDA Approved Vapes Starting September 1

[3] Reuters: BAT to Launch Synthetic Nicotine Vape Vuse One in U.S., Hitting Shelves in Three States from Late September

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com